so if you look at it in detail
rare disease like FSGS has a higher COS from phase 2 to 3 sitting at around 50%! then phase 3 COS goes to 73%.
As i stated - 30% cos is about right for phase 2 trials like DKD however given it has already passed phase 2a i would suggest the COS for phase 2b would be higher, however i cant find any actual stats on this.
so if you look at it in detailrare disease like FSGS has a...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.010(2.78%) |
Mkt cap ! $192.3M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 37.0¢ | 34.0¢ | $1.977M | 5.663M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 1445485 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 24999 | 1 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
34.5¢ |
Change
-0.010 ( 4.14 %) |
||||
| Open | High | Low | Volume | ||
| 36.5¢ | 37.0¢ | 34.0¢ | 2600347 | ||
| Last updated 15.59pm 06/05/2024 ? | |||||
| DXB (ASX) Chart |